Berenberg, a German investment bank, has raised its price target for Belgian drugmaker UCB to €320 from €305, after the company’s management pointed to stronger-than-expected demand for its key medicines. The bank also lifted its 2026–2028 forecasts, citing “low twenties” revenue growth for 2026 and a “low to mid-forties” rise in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).
The upgrade follows a conversation with UCB’s CFO, Sandrine Dufour, who highlighted that the next phase of growth is increasingly driven by higher volumes rather than price increases. That distinction matters for investors because volume-led growth can create operating leverage—meaning that once the fixed costs of manufacturing, sales, and overhead are covered, each additional unit sold adds more to the bottom line than to the top line.
What’s driving UCB’s growth?
UCB’s two main growth engines are Bimzelx (bimekizumab), a treatment for psoriasis and other inflammatory conditions, and Cimzia (certolizumab pegol), an older anti-inflammatory drug. Both have seen demand pick up, and management’s guidance suggests that momentum will continue into 2026 and beyond.
Berenberg’s analysts now expect UCB to deliver “low twenties” revenue growth in 2026, up from earlier estimates. They also project adjusted EBITDA growth in the “low to mid-forties” range, which is notably faster than sales growth. That gap is the essence of operating leverage: as UCB sells more units, its profit margins widen because many costs—like research and development, regulatory filings, and sales infrastructure—do not rise in lockstep with volume.
The bank still assumes some gradual price erosion, a common feature in the pharmaceutical industry as competition and payer pressure mount. But the key takeaway is that UCB’s growth is not reliant on holding prices; it’s coming from selling more medicine.
Clinical catalysts ahead
Berenberg also flagged a fuller pipeline of clinical-trial catalysts after a relatively quiet 2026. Among the most anticipated are late-stage data for Bimzelx in palmoplantar pustulosis, a difficult-to-treat skin condition, and mid-stage readouts for other pipeline programs. These results could shape how durable investors believe UCB’s demand story is into 2027 and beyond.
If the trials are positive, they could open new markets for Bimzelx and reinforce the volume-led growth narrative. If they disappoint, the market might question whether UCB can sustain its current trajectory. For now, Berenberg’s confidence is based on the strength of existing demand and the potential for additional indications.
What it means for investors
For everyday investors, the key number to watch is not just the “low twenties” sales growth—it’s the implied margin expansion. When a company can grow profits faster than sales, it often signals that the business is becoming more efficient and that each new sale is more profitable. That is why Berenberg’s price target move matters: it reflects a belief that UCB’s margins will keep widening.
The shift in focus from “will pricing fade?” to “can volumes stay strong enough to keep margins widening?” is a subtle but important change. If volumes hold up, UCB could deliver profit growth that outpaces its revenue growth for several years, which would support a higher valuation. If volumes falter, the margin story weakens, and the stock could lose its premium.
Berenberg’s €320 target is based on those “low to mid-forties” profit growth assumptions. It’s a signal that the bank sees UCB as a company whose growth is becoming more sustainable—and less dependent on pricing power that could erode.
For context, UCB is not alone in relying on volume growth. Many pharmaceutical companies face similar dynamics as their blockbuster drugs face competition. The ability to grow volumes while managing costs is a hallmark of a well-run drugmaker, and it’s a key reason why analysts are paying close attention to UCB’s pipeline and commercial execution.
As always, investors should remember that price targets are just one analyst’s view, and actual results can differ. But the direction of Berenberg’s move—up, with a clear rationale—offers a useful lens on how the market is thinking about UCB’s future.
